Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: CRH stock price vs XRAY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at XRAY's multiple
Needs XRAY P/E.
Implied fair value · at CRH's multiple
Needs EPS (TTM) is negative, CRH P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CRH FY 2025 (ended Dec 31, 2025) · XRAY FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
CRH public limited company · implied price per share
Bear
$61.82
Base
$72.72
Bull
$83.63
DENTSPLY SIRONA Inc. · implied price per share
Bear
-$16.64
Base
-$19.57
Bull
-$22.51
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.75x
1.93x
Net debt / EBITDA
Leverage against operating earnings
1.75x
125.72x
Cash and equivalents
Liquid reserves on the balance sheet
$4.10B
$326.04M
Total debt
Interest-bearing obligations outstanding
$18.71B
$2.59B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe CRH's current operating strength and historical/DCF valuation ranges are more relevant than the distorted XRAY comp, then avoid using XRAY-implied price as a sell signal because the data show CRH is fundamentally far stronger than XRAY.
The valuation gap is extreme: CRH trades at $107.56 versus an implied price of $40.75 on XRAY P/S framework, which indicates -62.1% downside from the current price. The gap is driven by XRAY's weak fundamentals and distorted multiples, including negative earnings and very high leverage, which make it a poor direct comp for CRH.
Supporting Metrics
Live quote
